乳腺癌蒽环类药物辅助化疗后肝功能损害与HBV激活的临床研究  

Clinical analysis of Hepatitis B reactivation and liver damage after anthracycline-based adjuvant chemotherapy in breast cancer patients

作　　者：龚建忠[1] 陈彦帆[1] 韦燕[1] 赵善琳[1] 张芸[1] 宁春玉[1] 

机构地区：[1]贵港市人民医院,广西贵港537100

出　　处：《海南医学》2012年第12期4-6,共3页Hainan Medical Journal

摘　　要：目的研究乳腺癌蒽环类药物辅助化疗患者肝功能改变以及化疗前合并HBV感染者乙肝病毒激活情况。方法回顾性分析采用含有蒽环类化疗药物治疗乳腺癌术后辅助化疗患者98例,其中合并HBV感染者25例。化疗采用CAF或CEF方案。结果合并有HBV感染的乳腺癌化疗后肝功能损害比例较高。20%(5/25)的患者合并有乙肝病毒激活,48%(12/25)的患者出现肝功能损害,Ⅲ度肝功能损害占8%(2/25)。无化疗相关死亡病例。结论 HBV感染的乳腺癌患者在应用蒽环类药物辅助化疗期间出现乙肝病毒明显激活,肝功能损害较非HBV感染者明显。Objective To investigate the changes of liver function in breast cancer patients after anthracy- cline-based adjuvant chemotherapy, as well as activation of Hepatitis B virus （HBV）. Methods The clinical data of 98 breast cancer patients after postoperative anthracycline-based adjuvant chemotherapy were analyzed, including 25 patients complicated with I-IBV infection. CAF or CEF scheme was used for chemotherapy. Results After chemo- therapy, a higher proportion of liver damage was investigated in the HBV-infected patients. Among the 25 patients, 5 （20%） were found with activation of HBV, 12 were found with hepatic dysfunction （48%）, including 2 （8%）of degree HI. No chemotherapy-related death occurred. Conclusion Breast cancer patients with I-IBV infection showed activa- tion of HBV after anthracycline-based adjuvant chemotherapy, in which the hepatic dysfunction is more serious than those without HBV infection.

关 键 词：乳腺癌 化学治疗 乙肝病毒 

分 类 号：R737.9[医药卫生—肿瘤]